The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies

Cynthia Gyamfi, Amanda L. Horton, Valerija Momirova, Dwight J. Rouse, Steve N. Caritis, Alan M. Peaceman, Anthony Sciscione, Paul J. Meis, Catherine Y. Spong, Mitchell Dombrowski, Baha Sibai, Michael W. Varner, Jay D. Iams, Brian M. Mercer, Marshall W. Carpenter, Julie Lo, Susan M. Ramin, Mary Jo O'Sullivan, Menachem Miodovnik, Deborah Conway

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Objective: To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo. Study Design: Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo. Results: We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73). Conclusion: Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.

Original languageEnglish (US)
Pages (from-to)392.e1-392.e5
JournalAmerican Journal of Obstetrics and Gynecology
Issue number4
StatePublished - Oct 2009
Externally publishedYes


  • 17-α hydroxy progesterone caproate
  • gestational diabetes
  • singletons
  • twins

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies'. Together they form a unique fingerprint.

Cite this